Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

Several possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-α) and melphalan after isolated limb perfusion (ILP) have been presented. We found a significant sixfold increase in melphalan tumour tissue concentration after ILP when TNF-α was added to the perfusate, which provides a straightforward explanation for the observed synergism between melphalan and TNF-α in ILP. © 2000 Cancer Research Campaign

[1]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[2]  A. Eggermont,et al.  In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats , 1999, British Journal of Cancer.

[3]  H. Alexander,et al.  Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  A. Eggermont,et al.  Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. , 1998, The Journal of surgical research.

[5]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[6]  G. Bieler,et al.  Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. , 1998, Nature medicine.

[7]  A. Eggermont,et al.  Determination of melphalan and hydrolysis products in body fluids by GC-MS , 1997 .

[8]  C. Wiltschke,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. B. Borel Rinkes,et al.  Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. , 1997, British Journal of Cancer.

[10]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[11]  A. Eggermont,et al.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.

[12]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. K. Jain,et al.  Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. , 1996, British Journal of Cancer.

[14]  A. Eggermont,et al.  Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.

[15]  A. Eggermont,et al.  VWF release and platelet aggregation in human melanoma after perfusion with TNFα , 1995, The Journal of pathology.

[16]  A. Eggermont,et al.  Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) , 1994 .

[17]  W. Travis,et al.  Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. , 1994, The Annals of thoracic surgery.

[18]  N. Tsuji,et al.  Enhancement of Blood Stasis and Vascular Permeability in Meth‐A Tumors by Administration of Hyperthermia in Combination with Tumor Necrosis Factor , 1994, Japanese journal of cancer research : Gann.

[19]  A. Eggermont,et al.  Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). , 1994, International journal of cancer.

[20]  F. Buchegger,et al.  Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability , 1993, International journal of cancer.

[21]  T. Ulich,et al.  Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. , 1992, The American journal of pathology.

[22]  S D Prionas,et al.  Dual role of tumor necrosis factor-alpha in angiogenesis. , 1992, The American journal of pathology.

[23]  S. Baba,et al.  Therapeutic effects of liposomal adriamycin in combination with tumor necrosis factor‐α , 1992, Journal of surgical oncology.

[24]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Nitanai,et al.  Augmentation for intratumoral accumulation and anti‐tumor activity of liposome‐encapsulated adriamycin by tumor necrosis factor‐α in mice , 1990, International journal of cancer.

[26]  B. Kroon,et al.  Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities , 1989, Cancer.

[27]  J. Mori,et al.  Recombinant human tumor necrosis factor‐α: Thrombus formation is a cause of anti‐tumor activity , 1988, International journal of cancer.